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Abstract 
Introduction: The increasing number of patients with end-stage renal disease (ESRD) requires seeking new opportunities to improve their 
quality of life, not only because of kidney disease but also due to other disturbances, such as thyroid hormone disorders.
The objective of the study was to evaluate the influence of coexisting hypothyroidism and thyroid hormone therapy in patients with 
ESRD on thyroid hormone conversion ratios and rT3 concentration.
Material and methods: The study involved 85 patients aged 26 to 87 years, with a mean age of 59.62 ± 15.45 years. Four groups of patients 
were examined: G1 group — 25 persons without RF and hypothyroidism, G2 — 26 patients with ESRD treated with haemodialysis (HD), 
G3 — 12 patients with ESRD treated with HD and newly diagnosed hypothyroidism, and G4 — 22 HD patients with hypothyroidism 
treated with thyroid hormones substitution.
The concentrations of TSH, T4, T3, fT4, fT3, and rT3 were measured and the fT3/fT4, T3/T4, and rT3/T4 conversion ratios and rT3/T3 ratio 
were calculated. Concentrations of protein, hsCRP, Hg, and blood gases were also checked; the anion gap was calculated.
Results: Patients from group G1 through G2 to G3 were older (ptrend = 0.002), with lower Hb level (ptrend < 0.001), with lower pH (ptrend 
< 0.001), with increased anion gap (ptrend < 0.013) and CRP concentrations (ptrend < 0.001), and decreased total protein level (ptrend < 0.001). 
There were increased TSH values (ptrend < 0.001) and lower T4 (ptrend = 0.024), fT3 (ptrend < 0.001), T3 (ptrend < 0.001), and rT3 (ptrend 
= 0.008) levels. rT3/T3 ratio did not change, the rT3/T4 ratio tended to decrease (ptrend = 0.065) similarly to T3/T4 ratio (ptrend = 0.063), and 
the fT3/fT4 ratio also decreased (ptrend = 0.005). It seems that the treatment of thyroid disease in patients with renal failure, treated with 
haemodialysis, is not associated with change of rT3 and conversion factor levels.
Conclusions: The concentration of rT3 in HD patients in relation to healthy persons tends to decrease, and hypothyroidism increases 
this tendency in these patients. Hormone substitution treatment does not eliminate the influence of RF on inhibition of rT3 production. 
In patients with ESRD, hypothyroidism additionally reduces the conversion of thyroid hormones examined by fT3/fT4 and to a lesser 
extent T3/T4 ratios. (Endokrynol Pol 2019; 70 (2): 165–171)
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Introduction 
The number of patients with chronic kidney disease 
(CKD), including patients on renal replacement ther-
apy, is constantly rising. Despite the increasing use of 
dialysis, mortality and morbidity in these groups of 
patients is still high and the quality of life is low [1, 2].
In CKD patients, disorders in other organs and 
systems also occur. One of the disorders is hypothyroid-
ism, which, both overt and subclinical, is found more 
frequently than in the general population. Disorders 
of thyroid hormone metabolism in patients with CKD 
are associated with an increase in the concentration of 
uremic toxins that selectively inhibit the transcriptional 
activity by blocking triiodothyronine (T3) receptors. At 
the same time, acidosis and high parathyroid hormone 
(PTH) concentration in secondary hyperparathyroid-
ism impair the conversion of thyroxine (T4 toT3, and 
an increase in phosphate ion concentration may lead 
to disturbance of T4 binding to transport proteins and 
an decrease in concentration of free thyroxine (fT4) 
fraction [3–5].
In patients with end-stage renal disease (ESRD) 
a significant reduction in T3 production is found. How-
ever, in contrast to other chronic diseases, no increase in 
rT3 concentration in RF is observed because impaired 
T4 toT3 conversion does not increase the activity of the 
pathway for the production of rT3 [3, 4, 6].
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— 64.0%) but not in the group with ESRD and normal 
thyroid function (G2 only 38.5%). The number of females 
and males in the group with RF and newly diagnosed 
hypothyroidism (G3) was comparable (50% each). 
Patients from group G1 through G2 to G3 were older 
(ptrend = 0.002), with lower Hb level (ptrend < 0.001), lower 
pH (ptrend < 0.001), increased anion gap (ptrend < 0.013) 
and CRP concentrations (ptrend < 0.001), and de-
creased total protein level (ptrend < 0.001) (Tab. I).
As shown in Table II, along with the transition from 
group G1 through G2 to G3, there were increased TSH 
values (ptrend < 0.001) and lower fT4 (ptrend<  0.001), 
T4 (ptrend = 0.024), fT3 (ptrend < 0.001), and T3 
(ptrend < 0,001) levels. rT3 values were also decreased 
(ptrend = 0,008), especially in both groups treated with 
haemodialysis in relation to the group of healthy people 
(G3 — ptrend = 0.008) (Tab. II).
Further analysis of the examined groups from G1 to 
G3 shows that: rT3/T3 ratio basically did not change, 
rT3/T4 ratio tended to decrease (ptrend = 0.065) similarly 
to T3/T4 ratio (ptrend = 0.063), and fT3/fT4 ratio was also 
decreased (ptrend = 0.005). Despite the fT3/fT4 trend 
shown, ESRD patients without hypothyroidism (G2) 
did not differ from the control group (G1) (p = 0.558). 
There was a significant difference between the control 
group (G1) and the group of patients with ESRD and 
with hypothyroidism (G3) (p = 0.002) and groups with 
renal failure without hypothyroidism (G2) and with 
hypothyroidism (G3) (p = 0.041) (Tab. III).
It seems that the treatment of thyroid disease in 
patients with ESRD, treated with haemodialysis, is not 
associated with change of rT3, conversion ratios, and 
rT3/T3 ratio (Tab. IV).
Discussion
Subclinical or overt hypothyroidism is diagnosed 
in many ESRD patients. Hormonal disturbances, as 
several researchers have noted, intensify with the de-
velopment of RF [1, 2]. A number of factors influence 
the above-mentioned disorders, the isolation of which 
is important for understanding the pathogenesis of 
hormonal disturbances.
The study assessed the influence of coexisting hypo-
thyroidism as well as substitution treatment on conver-
sion ratios and rT3/T3 ratio in patients with RF, in whom 
concentrations of thyroid hormones, both total and free 
fractions, are frequently decreased [3, 4]. The reason for 
the reduction in the concentration of thyroid hormones 
is abnormalities resulting from disorders of thyroid 
hormone synthesis, hormone degradation, conversion 
and transport with the participation of proteins. The 
regulation of the hypothalamus-pituitary-thyroid axis 
is also disturbed [7].
The inclusion of substitution treatment and nor-
malisation of thyroid hormone and TSH concentrations 
in patients with ESRD can have a beneficial effect on 
kidney function [2, 3].
Despite this knowledge, it is not established whether 
the conversion of thyroid hormones is significantly dif-
ferent in patients with hypothyroidism and coexisting 
RF, and how this situation affects rT3 concentrations.
The aim of the study
The objective of the study was to evaluate the influence 
of coexisting hypothyroidism and thyroid hormone 
therapy in patients with ESRD on thyroid hormone 
conversion ratios and rT3 concentration.
Material and methods 
The study involved 85 patients aged 26 to 87 years, with a mean age 
of 59.62 ± 15.45 years. Forty-six women and 39 men were examined, 
including: G1 group — 25 persons (F16, M9) aged 28–83 years, 
with mean age of 51.24 ± 12.58 without RF and hypothyroidism, 
G2 — 26 patients (F10, M16) aged 26–82 years with mean age of 
58.85 ± 15.52 years with ESRD treated with haemodialysis (HD), 
G3 — 12 patients (F6, M6) aged 37–83 with mean age of 66.80 ± 
12.90 years with ESRD treated with HD and newly diagnosed 
hypothyroidism, and G4 — 22 HD patients (F14, M8) aged 31–87 
years with mean age of 66.14 ± 15.54 with hypothyroidism treated 
substitutionally with thyroid hormones.
In all patients the following tests were performed: gasometry, total 
protein, C-reactive protein (CRP), creatinine, urea, TSH, and thyroid 
hormone concentrations: total thyroxine (T4), total triiodothyronine 
(T3), free thyroxine (fT4) fraction, free triiodothyronine (fT3) frac-
tion, and rT3. The fT3/fT4, T3/T4, rT3/T4, and rT3/T3 conversion 
ratios were calculated. 
The anion gap (AG) for the studied groups was calculated accord-
ing to the equation (AG = [Na+] – ([Cl−] + [HCO3]). Patients with 
ESRD treated in the HD program were examined on a scheduled 
dialysis day.
Statistical analysis
Basic descriptive statistics were used, and verification of hypotheses 
regarding comparisons between two groups was performed using 
Student’s t-test or the Mann-Whitney nonparametric test depend-
ing on the fulfilment of the assumptions regarding the distribution 
of the examined variables. Verification of hypotheses regarding 
comparisons between more than two groups was performed us-
ing analysis of variance or the Kruskal-Wallis nonparametric test 
(depending on the distribution). Bonferroni correction for multiple 
testing was applied. Trend analysis was performed using the linear 
trend test in the analysis of variance or the Jonckheere-Terpstra test. 
In the case of categorical variables, the chi-square test or the Fisher 
test were used, also for the linear trend. The significance level of 
0.05 was adopted.
Results
 Eighty-five patients were examined in groups G1 to G4. 
The groups did not differ in terms of gender (p = 0.189 
and p = 0.440) although females prevailed in the group 
with ESRD and treated hypothyroidism (G4 — 63.6%) 
and in the group without RF and hypothyroidism (G1 
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Table I. Characteristics of studied groups
Group Age Hb pH HCO3 Anion gap* CRP* Total protein
G3
ESRD, newly diagnosed 
hypothyroidism
No. 12 12 12 12 9 12 12
Mean 66.83 9.84 7.28 22.29 12.78 3.31 6.10
SD 12.90 1.84 0.07 2.78 5.70 2.62 0.88
Median 68.00 9.70 7.26 22.60 14.00 3.25 5.85
Minimum 37 7.5 7.2 17.1 2.0 0.3 4.8
Maximum 83 13.5 7.4 26.6 20.0 7.6 7.5
G2
ESRD, without 
hypothyroidism
No. 26 26 26 26 26 26 26
Mean 58.85 11.07 7.32 24.48 13.38 0.845 6.72
SD 15.522 2.17 0.07 2.77 5.90 0.67 0.67
Median 60.00 10.85 7.32 24.50 14.00 0.70 6.85
Minimum 26 8.4 7.2 18.6 0.0 0.10 5.3
Maximum 82 19.4 7.5 31.2 21.0 2.4 7.7
G1
Without RF, without 
hypothyroidism
No. 25 24 25 25 13 21 25
Mean 51.24 13.67 7.37 27.94 7.38 0.26 7.03
SD 12.581 1.48 0.052 2.66 3.36 0.32 0.56
Median 51.00 14.05 7.36 27.90 7.00 0.20 7.00
Minimum 28 11.1 7.3 23.3 3.0 0.0 5.8
Maximum 83 16.5 7.5 34.1 16.0 1.4 8.1
ptrend 0.002 < 0.001 < 0.001 < 0.001 0.013 < 0.001 < 0.001
p 0.007 < 0.001 0.001 < 0.001 0.028 < 0.001 0.001
pG1 vs. G2 0.168 < 0.001 0.047 < 0.001 0.006 0.001 0.318
pG2 vs. G3 0.317 0.196 0.161 0.075 1.000 0.099 0.028
pG1 vs. G3 0.007 < 0.001 0.001 < 0.001 0.083 < 0.001 0.001
*ptrend — value from Jonckheere-Terpstra test, in other cases — p-value from analysis of variance test, p from Kruskal-Wallis test, in other cases — p-value from 
analysis of variance test; pG1 vs. G2, pG2 vs. G3, pG1 vs. G3  for Bonferroni correction for multiple testing; ESRD — end-stage renal disease; RF — renal failure; 
Hb — haemoglobin; HCO3 — bicarbonate; CRP 33 C-reactive protein
Table II. Concentrations of thyroid hormones and TSH in studied groups
Group TSH* T4 T3 fT4 fT3 rT3*
G3
ESRD, newly diagnosed 
hypothyroidism
No. 12 11 11 12 12 11
Mean 13.56 83.67 1.14 12.02 2.35 226.75
SD 15.50 28.24 0.30 3.07 1.11 143.07
Median 7.74 84.82 1.11 12.08 2.03 216.39
Minimum 4.20 35.39 0.64 6.21 1.14 24.32
Maximum 58.10 121.60 1.60 16.78 4.60 415.73
G2
ESRD, without 
hypothyroidism
No. 26 23 23 26 26 23
Mean 1.62 93.37 1.54 14.87 3.77 253.97
SD 0.97 25.24 0.43 2.61 1.00 187.37
Median 1.32 91.80 1.45 14.40 3.51 174.70
Minimum 0.42 52.47 0.93 10.80 2.44 34.10
Maximum 4.03 167.90 2.63 20.42 7.06 719.32
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Table III. Thyroid hormone conversion ratios and rT3/fT3 ratio in studied groups
Group rT3/T3* rT3/T4* T3/T4 fT3/fT4
G3
ESRD, newly diagnosed hypothyroidism
No. 11 11 11 12
Mean 216.81 2.87 0.015 0.196
SD 182.23 2.39 0.004 0.070
Median 166.45 1.78 0.013 0.189
Minimum 29.23 0.69 0.010 0.08
Maximum 651.62 8.26 0.020 0.32
G2
ESRD, without hypothyroidism
No. 23 23 23 26
Mean 173.57 2.93 0.017 0.264
SD 137.98 2.25 0.006 0.093
Median 110.55 2.06 0.017 0.251
Minimum 22.58 0.43 0.01 0.13
Maximum 609.60 8.11 0.03 0.53
G1
Without RF, without hypothyroidism
No. 20 20 25 25
Mean 205.80 3.66 0.018 0.281
SD 91.30 1.37 0.003 0.058
Median 198.38 3.62 0.018 0.277
Minimum 44.68 0.61 0.01 0.18
Maximum 408.75 5.50 0.03 0.42
ptrend 0.338 0.065 0.063 0.005
P 0.260 0.130 0.140 0.003
pG1 vs. G2 0.558
pG2 vs. G3 0.041
pG1 vs. G3 0.002
*ptrend-value from Jonckheere-Terpstra test, in other cases — p-value from analysis of variance test; p from Kruskal-Wallis test, in other cases — p-value from analysis 
of variance test, pG1 vs. G2, pG2 vs. G3, pG1 vs. G3  for Bonferroni correction for multiple testing; ESRD — end-stage renal disease; RF — renal failure; TSH — thyroid stimulating 
hormone; T4 — thyroxine; T3 — triiodothyronine; fT4 —  free thyroxine; fT3 — free triiodothyronine
Table II. Concentrations of thyroid hormones and TSH in studied groups
Group TSH* T4 T3 fT4 fT3 rT3*
G1
Without RF, without  
hypothyroidism
No. 25 25 25 25 25 20
Mean 1.43 102.18 1.80 16.59 4.60 378.59
SD 0.95 16.41 0.34 2.61 0.92 157.28
Median 1.10 100.50 1.72 15.83 4.48 372.30
Minimum 0.43 76.46 1.19 12.70 2.69 73.73
Maximum 4.07 138.00 2.43 22.27 6.36 689.23
ptrend < 0.001 0.024 < 0.001 < 0.001 < 0.001 0.008
p < 0.001 0.075 < 0.001 < 0.001 < 0.001 0.020
pG1 vs. G2 1.000 0.054 0.080 0.001 0.048
pG2 vs. G3 < 0.001 0.016 0.011 < 0.001 1.000
pG1 vs. G3 < 0.001 < 0.001 < 0.001 < 0.001 0.058
*ptrend-value from Jonckheere-Terpstra test, in other cases — p-value from analysis of variance test; p from Kruskal-Wallis test, in other cases — p-value from analysis 
of variance test, pG1 vs. G2, pG2 vs. G3, pG1 vs. G3  for Bonferroni correction for multiple testing; ESRD — end-stage renal disease; RF — renal failure; T4 — thyroxine; 
T3 — triiodothyronine; fT4 —  free thyroxine; fT3 — free triiodothyronine
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T4 and fT4 concentrations in RF may be normal 
or slightly reduced, but dialysis patients may show 
increased fT4 and decreased T4 concentration, which 
is probably associated with T4-protein binding disor-
ders caused by heparin administered during HD [5, 8, 
9]. In the presented study, decreased values of T4, fT4, 
T3, and fT3 were also found in HD patients with the 
lowest concentration of fT4, T3, and fT3 in HD patients 
with newly diagnosed hypothyroidism, which may 
result from worse general condition of patients (Tab. II). 
Similar, but less significant, tendencies were found for 
total T4 concentrations (ptrend = 0.024). The group of 
HD patients with newly diagnosed hypothyroidism 
had the worst laboratory results (lowest Hb, highest 
CRP, lowest total protein, lowest pH and bicarbonate), 
which can also disturb thyroid hormone metabolism 
(Tab. I). Similar relationships for thyroid hormones 
were observed by other researchers who associated 
decreased T4 concentrations with acidosis, reduced 
albumin concentration and anaemia [3, 7, 8, 10]. Ad-
ditionally, the literature showed a negative correlation 
of total T4 concentration with urea [9].
The low concentration of total T3 in CKD patients 
appears to be one of the most important causes of 
mortality in euthyroid patients and may affect up to 
39% of CKD patients [1, 2, 11, 12]. Our study showed 
statistically significant lower T3 and fT3 concentrations 
in all examined groups of HD patients as compared to 
control group (Tab. II). Our results are confirmed by 
other investigators [11–14]. The reduction of T3 concen-
tration results from a reduction of 5’-deiodinase (D1) 
activity and an increase in 5-deiodinase (D3) activity, 
but not from a decrease in T4 availability [11–14]. In the 
population of patients with ESRD, low concentration of 
total T3 may also have been due to removing the free 
hormone through HD, reduced number of T3 bind-
ings, increased catabolism of the hormone, decreased 
T3 secretion by the thyroid gland, and finally, reduced 
T4 to T3 non-thyroidal conversion [12–15].
In the presented study, in the groups of ESRD pa-
tients treated with haemodialysis, we found elevated 
CRP concentration (≥ 0.8 mg/dl) especially in patients 
with newly diagnosed hypothyroidism (Tab. I). The as-
sociation of elevated concentrations of CRP and proin-
flammatory cytokines as well as decreased albumin and 
Hb concentrations with total T3 has also been shown 
by other researchers [3, 16, 17].
Despite worse prognosis in patients with ESRD, the 
indications for treatment of low T3 syndrome remain 
uncertain. While administration of levothyroxine ef-
fectively increased total T4 concentration to a level 
sometimes higher than normal, total T3 concentration 
remained higher but still low (Tab. IV). These data, 
combined with a low T3/T4 ratio, suggest that low 
concentration of total T3 in uremic patients may be due 
to abnormal peripheral thyroid hormone conversion 
(Tab. III). Similar suggestions can be found in other 
papers [3, 18].
Elevated rT3 concentration is characteristic of severe 
chronic diseases and is associated with worse prognosis 
and shorter survival, especially in older people [4, 19, 
20]. This situation is probably explained by decreased 
D1 activity, decreased rT3 uptake by the liver and the 
increased D3 activity [14, 15, 21]. In patients with RF the 
lack of elevation in total rT3 concentration is observed 
because in these patients the lower T4 to T3 conversion 
Table IV. Concentrations of TSH, thyroid hormones, thyroid hormone conversion ratios, and rT3/fT3 ratio in treated 
hypothyroidism in HD patients
G4 
ESRD, treated hypothyroidism
G3 
ESRD, newly diagnosed hypothyroidism p
N Mean ± SD Median Range N Mean ± SD Median Range
TSH* 19 2.9 ± 2.45 1.56 0.14–8.56 12 13.56 ± 15.5 7.74 4.2–58.1 < 0.001
T4 20 90.54 ± 22.41 90.15 44.52–134.7 11 83.67 ± 28.24 84.82 35.39–121.6 0.462
T3 20 1.23 ± 0.3 1.22 0.59–1.94 11 1.14 ± 0.3 1.11 0.64–1.6 0.412
fT4 20 16.03 ± 3.98 15.37 9.95–26.18 12 12.02 ± 3.07 12.08 6.21–16.78 0.005
fT3 20 3.21 ± 1.37 2.93 1.54–8.24 12 2.35 ± 1.11 2.03 1.14–4.6 0.076
rT3* 20 198.72 ± 91.84 185.36 61.79–367.87 11 226.75 ± 143.07 216.39 24.32–415.73 0.650
rT3/T3* 20 169.60 ± 87.76 170.77 51.92–357.16 11 216.81 ± 182.23 166.45 29.23–651.62 0.710
rT3/T4* 20 2.32 ± 1.23 2.16 0.92–4.79 11 2.87 ± 2.39 1.78 0.69–8.26 0.773
T3/T4 20 0.014 ± 0.004 0.013 0.01–.03 11 0.015 ± 0.004 0.013 0.01–0.02 0.857
fT3/fT4 20 0.208 ± 0.086 0.182 0.11–.42 12 0.196 ± 0.070 0.189 0.08–0.32 0.703
*p-value from Mann-Whitney test, in other cases — p-value from t-Student test; ESRD — end-stage renal disease; TSH — thyroid stimulating hormone;  
T4 — thyroxine; T3 — triiodothyronine; fT4 —  free thyroxine; fT3 — free triiodothyronine; SD — standard deviation
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does not intensify the activity of the pathway for the 
production of rT3. The decrease in rT3 concentration 
is also explained by its redistribution from vessels to 
extravascular space and the increase of rT3 cellular 
uptake [23]. In the present study, lower rT3 values were 
observed in dialysis patients than in patients without 
RF. Hypothyroidism did not increase rT3 concentration, 
although in patients without RF and without hypothy-
roidism the rT3 concentration was elevated, which is 
consistent with the results of other researchers (Tab. 
II) [11, 14, 22].  
Replacement therapy with thyroid hormones did 
not increase rT3 concentrations in HD patients, which 
suggests that the pathway for the production of rT3 is 
blocked by the condition of renal failure; this seems to 
be an important statement of the presented work (Tab. 
IV). Positive correlation between concentrations of rT3 
and total protein was found in patients without ESRD, 
but this might be associated with the nutrition status of 
the patients [6, 23]. Treatment with thyroid hormones 
in this group of patients did not change the conversion 
rates (Tab. IV). The metabolic significance of these dis-
orders remains unclear and requires further research 
due to lack of accurate literature data.
Disorders of thyroid hormone metabolism in people 
with ESRD are a very common phenomenon, and the 
most frequent are disturbances in the thyroid hormone 
T4 to T3 conversion. The principal factor impacting 
the conversion of thyroid hormones is the activity 
of deiodinases. In order to determine the conversion 
ratio of thyroid hormones, conversion ratios (T3/T4, 
fT3/fT4, rT3/T4) and the rT3/T3 ratio are used, allow-
ing an estimation of the intensity of thyroid hormone 
metabolism [12, 26].
In the presented study, the values of fT3/fT4 
conversion ratio tend to be statistically significantly 
lower in the group of patients with RF, and the values 
of the T3/T4 ratio are on the borderline of statistical 
significance (Tab. III), which was also noted in the 
works of other researchers [11,24]. They believe that 
in patients with CKD the value of the T3/T4 conver-
sion ratio is reduced proportionally to the activity 
of D1 deiodinase [6, 11, 25]. In people with thyroid 
dysfunction, the T3/T4 conversion ratio also changes 
— in hypothyroidism its value decreases, and in hy-
perthyroidism it increases, which is also described in 
the literature [26].
Our study showed a tendency towards reduction 
of the rT3/T4 conversion ratios (on the borderline of 
statistical significance) in ESRD patients treated with 
HD (Tab. III), which is related to the activity of D3 
in the liver [11]. In patients treated with dialysis, D1 
activity is reduced and D3 activity is elevated [11, 24]. 
The rT3/T3 ratio was considered a very good marker 
reflecting disturbances of peripheral thyroid hormone 
metabolism in severe diseases, but we did not find any 
significant changes of this factor in our work (Tab. III) 
[11]. Data in the literature prove that the increase in 
the value of rT3/T3 ratio is associated with worse prog-
nosis and shorter survival, especially in older people 
[11, 18, 24].
Conclusions
The concentration of rT3 in ESRD patients treated with 
HD in relation to healthy persons tends to decrease, 
and hypothyroidism increases this tendency in these 
patients. Hormonal substitution treatment does not 
eliminate the influence of RF on inhibition of rT3 pro-
duction. In patients with ESRD, hypothyroidism ad-
ditionally reduces the conversion of thyroid hormones 
examined by fT3/fT4 and to a lesser extent T3/T4 ratios.
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